A homologous and molecular dual-targeted biomimetic nanocarrier for EGFR-related non-small cell lung cancer therapy

作     者：Bin Xu Fanjun Zeng Jialong Deng Lintong Yao Shengbo Liu Hengliang Hou Yucheng Huang Hongyuan Zhu Shaowei Wu Qiaxuan Li Weijie Zhan Hongrui Qiu Huili Wang Yundong Li Xianzhu Yang Ziyang Cao Yu Zhang Haiyu Zhou 

作者机构：Department of Thoracic SurgeryGuangdong Provincial People’s Hospital(Guangdong Academy of Medical Sciences)Southern Medical UniversityGuangzhou510080PR China Department of General PracticeGuangdong Provincial Geriatrics InstituteGuangdong Provincial People’s Hospital(Guangdong Academy of Medical Sciences)Southern Medical UniversityGuangzhou510080PR China Department of OrthopedicsGuangdong Provincial People’s Hospital(Guangdong Academy of Medical Sciences)Southern Medical UniversityGuangzhou510080GuangdongChina The Second School of Clinical MedicineSouthern Medical UniversityGuangzhou510515PR China Shantou University Medical CollegeShantou515063PR China Guangzhou University of Chinese MedicineGuangzhou510006PR China Guangzhou First People’s HospitalSouth China University of TechnologyGuangzhou510006PR China School of Biology and Biological EngineeringSouth China University of TechnologyGuangzhou510006PR China School of MedicineSouth China University of TechnologyGuangzhou510006PR China School of Biomedical Sciences and EngineeringSouth China University of TechnologyGuangzhou International CampusGuangzhou511442PR China South China Sea Fisheries Research InstituteChinese Academy of Fishery SciencesKey Laboratory of South China Sea Fishery Resources Exploitation and UtilizationMinistry of Agriculture and Rural AffairsGuangzhou510300China 

出 版 物：《Bioactive Materials》 (生物活性材料（英文）)

年 卷 期：2023年第27卷第9期

页      面：337-347页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：supported by the National Key R&D Program of China(No.2022YFD2401900) the National Natural Science Foundation of China(No.52203163) the High-level Hospital Construction Project(No.DFJH201905) the Natural Science Foundation of Guangdong(No.2021A1515010838) the International Science and Technology Cooperation Program of Guangdong(No.2022A0505050048) the Science and Technology Program of Guangzhou(No.201903010028) Guangdong Provincial People’s Hospital Intermural Program(No.KJ012019447) 

主　　题：Biomimetic nanoparticles Membrane targeting EGFR mutation Tyrosine kinase inhibitor Intracellular drug delivery Clinical efficacy Non-small cell lung cancer 

摘      要：The abnormal activation of epidermal growth factor receptor(EGFR)drives the development of non-small cell lung cancer(NSCLC).The EGFR-targeting tyrosine kinase inhibitor osimertinib is frequently used to clinically treat NSCLC and exhibits marked efficacy in patients with NSCLC who have an EGFR ***,free osimertinib administration exhibits an inadequate response in vivo,with only~3%patients demonstrating a complete clinical ***,we designed a biomimetic nanoparticle(CMNP^(@Osi))comprising a polymeric nanoparticle core and tumor cell-derived membrane-coated shell that combines membrane-mediated homologous and molecular targeting for targeted drug delivery,thereby supporting a dual-target strategy for enhancing osimertinib *** intravenous injection,CMNP^(@Osi)accumulates at tumor sites and displays enhanced uptake into cancer cells based on homologous *** is subsequently released into the cytoplasm,where it suppresses the phosphorylation of upstream EGFR and the downstream AKT signaling pathway and inhibits the proliferation of NSCLC ***,this dual-targeting strategy using a biomimetic nanocarrier can enhance molecular-targeted drug delivery and improve clinical efficacy.